Group finds Trump drug deals favor drugmakers over patients
Recovery Modalities

Group finds Trump drug deals favor drugmakers over patients

By emily johnson · 502 Views · September 23, 2026
Recovery Modalities

Three biotech firms eye Nasdaq listings

Three biotech firms—including ADARx Pharma—are preparing Nasdaq listings, with ADARx targeting a $1.74 billion valuation for its hereditary...

September 22, 2026

Editor's picks

All Post

Endocrine Balance

Simple fixes for NZ’s persistent home dampness

Simple fixes for NZ’s persistent home dampness, tackling musty odors and condensation in Waikato and beyond with practical ventilation and insulation s

Samoyed 236 Views September 25, 2026
Recovery Modalities

Three biotech firms eye Nasdaq listings

Three biotech firms—including ADARx Pharma—are preparing Nasdaq listings, with ADARx targeting a $1.74 billion valuation for its hereditary angioedema therapy.

Samoyed 93 Views September 22, 2026
Endocrine Balance

Biotech and Digital Health Firms Expand Boards

Board appointments are reshaping biotech and digital health firms as August brings seasoned executives and scientific leaders onto boards to drive growth.

Samoyed 200 Views September 21, 2026
Endocrine Balance

UK drug firms pull out of NICE reviews at record

UK drug firms are pulling out of NICE reviews at record levels in 2026, raising questions about industry shifts or systemic issues in the appraisal process.

Samoyed 223 Views September 19, 2026